News Releases
View printer-friendly version < < backNet earnings and diluted earnings per share for the second quarter of 2017 were
"Our second-quarter results reflect strong adjusted earnings growth and we are optimistic that the investments we are making will accelerate our sales growth in the second half of this year. Our pharmaceutical pipeline continued its strong momentum with the approval of TREMFYA™ as well as the submission and approval of several key line extensions," said
The Company increased its sales guidance for the full-year 2017 to
Worldwide Consumer sales of
Worldwide operational results, excluding the net impact of acquisitions and divestitures, were negatively impacted by baby care products, partially offset by domestic over-the-counter products, including upper respiratory products and international anti-smoking aids, and NEUTROGENA® beauty products.
Worldwide Pharmaceutical sales of
Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by new products and the strength of core products. Strong growth in new products include DARZALEX® (daratumumab), for the treatment of patients with multiple myeloma and IMBRUVICA® (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. Additional contributors to operational sales growth included STELARA® (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, and INVEGA® SUSTENNA®/XEPLION®/TRINZA® (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults.
During the quarter, the Company announced the completion of the acquisition of Actelion Ltd., a leading biopharmaceutical company, for a total purchase price of approximately
Also in the quarter, the
In addition, a supplemental New Drug Application was submitted to the
In July, subsequent to the quarter, the
Worldwide Medical Devices sales of
Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by electrophysiology products in the Cardiovascular business, ACUVUE® contact lenses in the Vision Care business, and Advanced Surgery products, partially offset by declines in the Diabetes Care business.
During the quarter,
About
Caring for the world, one person at a time, inspires and unites the people of
* Operational sales growth excluding the net impact of acquisitions and divestitures, as well as adjusted net earnings, adjusted diluted earnings per share and operational adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at www.investor.jnj.com.
Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of
|
|||||||||||||||||||
Supplementary Sales Data |
|||||||||||||||||||
(Unaudited; Dollars in Millions) |
SECOND QUARTER |
SIX MONTHS | |||||||||||||||||
Percent Change |
Percent Change | ||||||||||||||||||
2017 |
2016 |
Total |
Operations |
Currency |
2017 |
2016 |
Total |
Operations |
Currency | ||||||||||
Sales to customers by |
|||||||||||||||||||
segment of business |
|||||||||||||||||||
Consumer |
|||||||||||||||||||
|
$ 1,487 |
1,384 |
7.4 |
% |
7.4 |
- |
$ 2,901 |
2,742 |
5.8 |
% |
5.8 |
- | |||||||
International |
1,991 |
2,035 |
(2.2) |
(1.1) |
(1.1) |
3,805 |
3,872 |
(1.7) |
(1.3) |
(0.4) | |||||||||
3,478 |
3,419 |
1.7 |
2.3 |
(0.6) |
6,706 |
6,614 |
1.4 |
1.6 |
(0.2) | ||||||||||
Pharmaceutical |
|||||||||||||||||||
|
5,010 |
5,144 |
(2.6) |
(2.6) |
- |
9,882 |
10,081 |
(2.0) |
(2.0) |
- | |||||||||
International |
3,625 |
3,510 |
3.3 |
6.1 |
(2.8) |
6,998 |
6,751 |
3.7 |
5.9 |
(2.2) | |||||||||
8,635 |
8,654 |
(0.2) |
1.0 |
(1.2) |
16,880 |
16,832 |
0.3 |
1.2 |
(0.9) | ||||||||||
Medical Devices |
|||||||||||||||||||
|
3,229 |
3,044 |
6.1 |
6.1 |
- |
6,321 |
6,070 |
4.1 |
4.1 |
- | |||||||||
International |
3,497 |
3,365 |
3.9 |
5.8 |
(1.9) |
6,698 |
6,448 |
3.9 |
5.3 |
(1.4) | |||||||||
6,726 |
6,409 |
4.9 |
5.9 |
(1.0) |
13,019 |
12,518 |
4.0 |
4.7 |
(0.7) | ||||||||||
|
9,726 |
9,572 |
1.6 |
1.6 |
- |
19,104 |
18,893 |
1.1 |
1.1 |
- | |||||||||
International |
9,113 |
8,910 |
2.3 |
4.4 |
(2.1) |
17,501 |
17,071 |
2.5 |
4.0 |
(1.5) | |||||||||
Worldwide |
|
18,482 |
1.9 |
% |
2.9 |
(1.0) |
|
35,964 |
1.8 |
% |
2.5 |
(0.7) |
|
|||||||||||||||||||
Supplementary Sales Data |
|||||||||||||||||||
(Unaudited; Dollars in Millions) |
SECOND QUARTER |
SIX MONTHS | |||||||||||||||||
Percent Change |
Percent Change | ||||||||||||||||||
2017 |
2016 |
Total |
Operations |
Currency |
2017 |
2016 |
Total |
Operations |
Currency | ||||||||||
Sales to customers by |
|||||||||||||||||||
geographic area |
|||||||||||||||||||
|
$ 9,726 |
9,572 |
1.6 |
% |
1.6 |
- |
|
18,893 |
1.1 |
% |
1.1 |
- | |||||||
|
4,232 |
4,090 |
3.5 |
6.7 |
(3.2) |
8,090 |
7,937 |
1.9 |
5.4 |
(3.5) | |||||||||
Western Hemisphere excluding |
1,499 |
1,542 |
(2.8) |
(2.7) |
(0.1) |
2,953 |
2,873 |
2.8 |
(0.2) |
3.0 | |||||||||
|
3,382 |
3,278 |
3.2 |
4.9 |
(1.7) |
6,458 |
6,261 |
3.1 |
4.1 |
(1.0) | |||||||||
International |
9,113 |
8,910 |
2.3 |
4.4 |
(2.1) |
17,501 |
17,071 |
2.5 |
4.0 |
(1.5) | |||||||||
Worldwide |
|
18,482 |
1.9 |
% |
2.9 |
(1.0) |
|
35,964 |
1.8 |
% |
2.5 |
(0.7) |
|
|||||||||
Condensed Consolidated Statement of Earnings |
|||||||||
(Unaudited; in Millions Except Per Share Figures) |
SECOND QUARTER | ||||||||
2017 |
2016 |
Percent | |||||||
Percent |
Percent |
Increase | |||||||
Amount |
to Sales |
Amount |
to Sales |
(Decrease) | |||||
Sales to customers |
|
100.0 |
|
100.0 |
1.9 | ||||
Cost of products sold |
5,823 |
30.9 |
5,336 |
28.9 |
9.1 | ||||
Selling, marketing and administrative expenses |
5,262 |
28.0 |
5,176 |
28.0 |
1.7 | ||||
Research and development expense |
2,285 |
12.1 |
2,264 |
12.2 |
0.9 | ||||
In-process research and development |
- |
- |
29 |
0.2 |
|||||
Interest (income) expense, net |
122 |
0.6 |
102 |
0.6 |
|||||
Other (income) expense, net |
588 |
3.1 |
557 |
3.0 |
|||||
Restructuring |
11 |
0.1 |
114 |
0.6 |
|||||
Earnings before provision for taxes on income |
4,748 |
25.2 |
4,904 |
26.5 |
(3.2) | ||||
Provision for taxes on income |
921 |
4.9 |
907 |
4.9 |
1.5 | ||||
Net earnings |
$ 3,827 |
20.3 |
$ 3,997 |
21.6 |
(4.3) | ||||
Net earnings per share (Diluted) |
$ 1.40 |
$ 1.43 |
(2.1) | ||||||
Average shares outstanding (Diluted) |
2,741.5 |
2,794.2 |
|||||||
Effective tax rate |
19.4 |
% |
18.5 |
% |
|||||
Adjusted earnings before provision for taxes and net earnings (1) |
|||||||||
Earnings before provision for taxes on income |
$ 6,285 |
33.4 |
$ 6,024 |
32.6 |
4.3 | ||||
Net earnings |
$ 5,017 |
26.6 |
$ 4,866 |
26.3 |
3.1 | ||||
Net earnings per share (Diluted) |
$ 1.83 |
$ 1.74 |
5.2 | ||||||
Effective tax rate |
20.2 |
% |
19.2 |
% |
|||||
(1) See Reconciliation of Non-GAAP Financial Measures. |
|
|||||||||
Condensed Consolidated Statement of Earnings |
|||||||||
(Unaudited; in Millions Except Per Share Figures) |
SIX MONTHS | ||||||||
2017 |
2016 |
Percent | |||||||
Percent |
Percent |
Increase | |||||||
Amount |
to Sales |
Amount |
to Sales |
(Decrease) | |||||
Sales to customers |
|
100.0 |
|
100.0 |
1.8 | ||||
Cost of products sold |
11,209 |
30.6 |
10,665 |
29.6 |
5.1 | ||||
Selling, marketing and administrative expenses |
9,999 |
27.3 |
9,864 |
27.4 |
1.4 | ||||
Research and development expense |
4,345 |
11.9 |
4,277 |
11.9 |
1.6 | ||||
In-process research and development |
- |
- |
29 |
0.1 |
|||||
Interest (income) expense, net |
205 |
0.6 |
179 |
0.5 |
|||||
Other (income) expense, net |
428 |
1.2 |
518 |
1.4 |
|||||
Restructuring |
96 |
0.2 |
234 |
0.7 |
|||||
Earnings before provision for taxes on income |
10,323 |
28.2 |
10,198 |
28.4 |
1.2 | ||||
Provision for taxes on income |
2,074 |
5.7 |
1,744 |
4.9 |
18.9 | ||||
Net earnings |
$ 8,249 |
22.5 |
$ 8,454 |
23.5 |
(2.4) | ||||
Net earnings per share (Diluted) |
$ 3.00 |
$ 3.02 |
(0.7) | ||||||
Average shares outstanding (Diluted) |
2,749.4 |
2,800.9 |
|||||||
Effective tax rate |
20.1 |
% |
17.1 |
% |
|||||
Adjusted earnings before provision for taxes and net earnings (1) |
|||||||||
Earnings before provision for taxes on income |
|
33.8 |
|
32.9 |
4.8 | ||||
Net earnings |
|
27.5 |
$ 9,720 |
27.0 |
3.4 | ||||
Net earnings per share (Diluted) |
$ 3.66 |
$ 3.47 |
5.5 | ||||||
Effective tax rate |
18.8 |
% |
17.8 |
% |
|||||
(1) See Reconciliation of Non-GAAP Financial Measures. |
|
||||||||||||||
Reconciliation of Non-GAAP Financial Measures |
||||||||||||||
Second Quarter |
% Incr. / |
Six Months YTD |
% Incr. / |
|||||||||||
(Dollars in Millions Except Per Share Data) |
2017 |
2016 |
(Decr.) |
2017 |
2016 |
(Decr.) |
||||||||
Earnings before provision for taxes on income - as reported |
|
4,904 |
(3.2) |
% |
|
10,198 |
1.2 |
% | ||||||
Intangible asset amortization expense |
480 |
326 |
809 |
608 |
||||||||||
Litigation expense, net |
493 |
600 |
493 |
666 |
||||||||||
Restructuring/Other (1) |
128 |
141 |
289 |
278 |
||||||||||
Actelion acquisition related cost |
213 |
- |
213 |
- |
||||||||||
Diabetes asset impairment |
182 |
- |
182 |
- |
||||||||||
AMO acquisition related cost |
41 |
- |
79 |
- |
||||||||||
In-process research and development |
- |
29 |
- |
29 |
||||||||||
Other |
- |
24 |
- |
46 |
||||||||||
Earnings before provision for taxes on income - as adjusted |
|
6,024 |
4.3 |
% |
|
11,825 |
4.8 |
% | ||||||
Net Earnings - as reported |
|
3,997 |
(4.3) |
% |
$ 8,249 |
8,454 |
(2.4) |
% | ||||||
Intangible asset amortization expense |
378 |
238 |
622 |
443 |
||||||||||
Litigation expense, net |
352 |
493 |
352 |
549 |
||||||||||
Restructuring/Other |
101 |
97 |
222 |
217 |
||||||||||
Actelion acquisition related cost |
199 |
- |
199 |
- |
||||||||||
Diabetes asset impairment |
125 |
- |
125 |
- |
||||||||||
AMO acquisition related cost |
35 |
- |
286 |
- |
||||||||||
In-process research and development |
- |
23 |
- |
23 |
||||||||||
Other |
- |
18 |
- |
34 |
||||||||||
Net Earnings - as adjusted |
|
4,866 |
3.1 |
% |
|
9,720 |
3.4 |
% | ||||||
Diluted Net Earnings per share - as reported |
$ 1.40 |
1.43 |
(2.1) |
% |
$ 3.00 |
3.02 |
(0.7) |
% | ||||||
Intangible asset amortization expense |
0.14 |
0.08 |
0.23 |
0.16 |
||||||||||
Litigation expense, net |
0.13 |
0.18 |
0.13 |
0.19 |
||||||||||
Restructuring/Other |
0.03 |
0.03 |
0.08 |
0.08 |
||||||||||
Actelion acquisition related cost |
0.07 |
- |
0.07 |
- |
||||||||||
Diabetes asset impairment |
0.05 |
- |
0.05 |
- |
||||||||||
AMO acquisition related cost |
0.01 |
- |
0.10 |
- |
||||||||||
In-process research and development |
- |
0.01 |
- |
0.01 |
||||||||||
Other |
- |
0.01 |
- |
0.01 |
||||||||||
Diluted Net Earnings per share - as adjusted |
$ 1.83 |
1.74 |
5.2 |
% |
$ 3.66 |
3.47 |
5.5 |
% | ||||||
Operational Diluted Net Earnings per share - as adjusted |
||||||||||||||
at 2015 foreign currency exchange rates |
1.74 |
3.51 |
||||||||||||
Impact of currency at 2016 foreign currency exchange rates |
0.03 |
- |
0.06 |
(0.04) |
||||||||||
Operational Diluted Net Earnings per share - as adjusted |
||||||||||||||
at 2016 foreign currency exchange rates |
$ 1.86 |
1.74 |
6.9 |
% |
$ 3.72 |
3.47 |
7.2 |
% | ||||||
(1)Includes |
|
||||||||
Reconciliation of Non-GAAP Financial Measure |
||||||||
Operational Sales Growth Excluding Acquisitions and Divestitures | ||||||||
SECOND QUARTER 2017 ACTUAL vs. 2016 ACTUAL | ||||||||
Segments | ||||||||
Consumer |
Pharmaceutical |
Medical Devices |
Total | |||||
Operational %(1) | ||||||||
WW As Reported: |
2.3% |
1.0% |
5.9% |
2.9% | ||||
U.S. |
7.4% |
(2.6)% |
6.1% |
1.6% | ||||
International |
(1.1)% |
6.1% |
5.8% |
4.4% | ||||
Beauty |
||||||||
|
(2.7) |
(0.5) | ||||||
U.S. |
(5.9) |
(0.9) | ||||||
International |
(0.6) |
(0.1) | ||||||
Other Neuroscience |
||||||||
Controlled Substance Raw Material and API Business |
0.6 |
0.3 | ||||||
U.S. |
0.8 |
0.4 | ||||||
International |
0.5 |
0.2 | ||||||
Diagnostics |
||||||||
|
0.5 |
0.2 | ||||||
U.S. |
0.0 |
0.0 | ||||||
International |
1.0 |
0.3 | ||||||
Vision Care |
||||||||
Abbott Medical Optics |
(5.1) |
(1.8) | ||||||
U.S. |
(4.6) |
(1.5) | ||||||
International |
(5.6) |
(2.1) | ||||||
Pulmonary Hypertension |
||||||||
Actelion |
(1.1) |
(0.5) | ||||||
U.S. |
(0.8) |
(0.4) | ||||||
International |
(1.5) |
(0.6) | ||||||
All Other Acquisitions and Divestitures |
(0.4) |
(0.2) |
(0.1) | |||||
U.S. |
(0.3) |
(0.7) |
(0.2) | |||||
International |
(0.6) |
0.2 |
(0.1) | |||||
WW Ops excluding Acquisitions and Divestitures |
(0.8)% |
0.5% |
1.1% |
0.5% | ||||
U.S. |
1.2% |
(2.6)% |
0.8% |
(1.0)% | ||||
International |
(2.3)% |
5.1% |
1.4% |
2.0% | ||||
(1)Operational growth excludes the effect of translational currency |
|
||||||||
Reconciliation of Non-GAAP Financial Measure |
||||||||
Operational Sales Growth Excluding Acquisitions and Divestitures | ||||||||
SIX MONTHS 2017 ACTUAL vs. 2016 ACTUAL | ||||||||
Segments | ||||||||
Consumer |
Pharmaceutical |
Medical Devices |
Total | |||||
Operational %(1) | ||||||||
WW As Reported: |
1.6% |
1.2% |
4.7% |
2.5% | ||||
U.S. |
5.8% |
(2.0)% |
4.1% |
1.1% | ||||
International |
(1.3)% |
5.9% |
5.3% |
4.0% | ||||
Beauty |
||||||||
|
(2.9) |
(0.5) | ||||||
U.S. |
(6.1) |
(0.9) | ||||||
International |
(0.7) |
(0.2) | ||||||
Other Neuroscience |
||||||||
Controlled Substance Raw Material and API Business |
0.7 |
0.3 | ||||||
U.S. |
0.9 |
0.5 | ||||||
International |
0.4 |
0.2 | ||||||
Diagnostics |
||||||||
|
0.5 |
0.2 | ||||||
U.S. |
0.0 |
0.0 | ||||||
International |
1.0 |
0.4 | ||||||
Vision Care |
||||||||
Abbott Medical Optics |
(3.6) |
(1.3) | ||||||
U.S. |
(3.2) |
(1.0) | ||||||
International |
(4.0) |
(1.5) | ||||||
Pulmonary Hypertension |
||||||||
Actelion |
(0.6) |
(0.3) | ||||||
U.S. |
(0.4) |
(0.2) | ||||||
International |
(0.8) |
(0.3) | ||||||
All Other Acquisitions and Divestitures |
(0.3) |
(0.2) |
(0.1) | |||||
U.S. |
(0.5) |
(0.7) |
(0.4) | |||||
International |
(0.1) |
0.2 |
0.1 | |||||
WW Ops excluding Acquisitions and Divestitures |
(1.6)% |
1.3% |
1.4% |
0.8% | ||||
U.S. |
(0.8)% |
(1.5)% |
0.2% |
(0.9)% | ||||
International |
(2.1)% |
5.5% |
2.5% |
2.7% | ||||
(1)Operational growth excludes the effect of translational currency |
REPORTED SALES vs. PRIOR PERIOD ($MM) |
|||||||||||||||||
SECOND QUARTER |
SIX MONTHS |
||||||||||||||||
% Change |
% Change |
||||||||||||||||
2017 |
2016 |
Reported |
Operational (1) |
Currency |
2017 |
2016 |
Reported |
Operational (1) |
Currency |
||||||||
CONSUMER SEGMENT (2) (3) |
|||||||||||||||||
|
|||||||||||||||||
US |
$ 113 |
$ 126 |
-10.3% |
-10.3% |
- |
$ 226 |
$ 247 |
-8.5% |
-8.5% |
- |
|||||||
Intl |
381 |
404 |
-5.7% |
-5.3% |
-0.4% |
723 |
766 |
-5.6% |
-5.7% |
0.1% |
|||||||
WW |
494 |
530 |
-6.8% |
-6.5% |
-0.3% |
949 |
1,013 |
-6.3% |
-6.3% |
0.0% |
|||||||
BEAUTY |
|||||||||||||||||
US |
649 |
554 |
17.1% |
17.1% |
- |
1,216 |
1,038 |
17.1% |
17.1% |
- |
|||||||
Intl |
427 |
422 |
1.2% |
3.1% |
-1.9% |
841 |
817 |
2.9% |
4.0% |
-1.1% |
|||||||
WW |
1,076 |
976 |
10.2% |
11.0% |
-0.8% |
2,057 |
1,855 |
10.9% |
11.4% |
-0.5% |
|||||||
|
|||||||||||||||||
US |
150 |
159 |
-5.7% |
-5.7% |
- |
306 |
329 |
-7.0% |
-7.0% |
- |
|||||||
Intl |
244 |
244 |
0.0% |
0.8% |
-0.8% |
450 |
459 |
-2.0% |
-1.7% |
-0.3% |
|||||||
WW |
394 |
403 |
-2.2% |
-1.7% |
-0.5% |
756 |
788 |
-4.1% |
-3.9% |
-0.2% |
|||||||
OTC |
|||||||||||||||||
US |
432 |
405 |
6.7% |
6.7% |
- |
909 |
871 |
4.4% |
4.4% |
- |
|||||||
Intl |
574 |
591 |
-2.9% |
-1.1% |
-1.8% |
1,110 |
1,124 |
-1.2% |
-0.2% |
-1.0% |
|||||||
WW |
1,006 |
996 |
1.0% |
2.1% |
-1.1% |
2,019 |
1,995 |
1.2% |
1.8% |
-0.6% |
|||||||
WOMEN'S HEALTH |
|||||||||||||||||
US |
3 |
7 |
-57.1% |
-57.1% |
- |
6 |
13 |
-53.8% |
-53.8% |
- |
|||||||
Intl |
273 |
276 |
-1.1% |
-1.9% |
0.8% |
512 |
521 |
-1.7% |
-3.0% |
1.3% |
|||||||
WW |
276 |
283 |
-2.5% |
-3.3% |
0.8% |
518 |
534 |
-3.0% |
-4.2% |
1.2% |
|||||||
WOUND CARE / OTHER |
|||||||||||||||||
US |
140 |
133 |
5.3% |
5.3% |
- |
238 |
244 |
-2.5% |
-2.5% |
- |
|||||||
Intl |
92 |
98 |
-6.1% |
-4.8% |
-1.3% |
169 |
185 |
-8.6% |
-8.3% |
-0.3% |
|||||||
WW |
232 |
231 |
0.4% |
0.9% |
-0.5% |
407 |
429 |
-5.1% |
-5.0% |
-0.1% |
|||||||
TOTAL CONSUMER |
|||||||||||||||||
US |
1,487 |
1,384 |
7.4% |
7.4% |
- |
2,901 |
2,742 |
5.8% |
5.8% |
- |
|||||||
Intl |
1,991 |
2,035 |
-2.2% |
-1.1% |
-1.1% |
3,805 |
3,872 |
-1.7% |
-1.3% |
-0.4% |
|||||||
WW |
$ 3,478 |
$ 3,419 |
1.7% |
2.3% |
-0.6% |
$ 6,706 |
$ 6,614 |
1.4% |
1.6% |
-0.2% |
|||||||
REPORTED SALES vs. PRIOR PERIOD ($MM) |
|||||||||||||||||
SECOND QUARTER |
SIX MONTHS |
||||||||||||||||
% Change |
% Change |
||||||||||||||||
2017 |
2016 |
Reported |
Operational (1) |
Currency |
2017 |
2016 |
Reported |
Operational (1) |
Currency |
||||||||
PHARMACEUTICAL SEGMENT (2) (3) |
|||||||||||||||||
IMMUNOLOGY |
|||||||||||||||||
US |
$ 2,101 |
$ 2,224 |
-5.5% |
-5.5% |
- |
$ 4,224 |
$ 4,395 |
-3.9% |
-3.9% |
- |
|||||||
Intl |
858 |
814 |
5.4% |
8.0% |
-2.6% |
1,665 |
1,553 |
7.2% |
8.5% |
-1.3% |
|||||||
WW |
2,959 |
3,038 |
-2.6% |
-1.9% |
-0.7% |
5,889 |
5,948 |
-1.0% |
-0.7% |
-0.3% |
|||||||
REMICADE |
|||||||||||||||||
US |
1,064 |
1,236 |
-13.9% |
-13.9% |
- |
2,246 |
2,447 |
-8.2% |
-8.2% |
- |
|||||||
US Exports (4) |
127 |
185 |
-31.4% |
-31.4% |
- |
292 |
418 |
-30.1% |
-30.1% |
- |
|||||||
Intl |
339 |
359 |
-5.6% |
-3.4% |
-2.2% |
664 |
694 |
-4.3% |
-4.0% |
-0.3% |
|||||||
WW |
1,530 |
1,780 |
-14.0% |
-13.6% |
-0.4% |
3,202 |
3,559 |
-10.0% |
-9.9% |
-0.1% |
|||||||
SIMPONI / SIMPONI ARIA |
|||||||||||||||||
US |
230 |
244 |
-5.7% |
-5.7% |
- |
459 |
460 |
-0.2% |
-0.2% |
- |
|||||||
Intl |
209 |
204 |
2.5% |
4.6% |
-2.1% |
408 |
378 |
7.9% |
8.6% |
-0.7% |
|||||||
WW |
439 |
448 |
-2.0% |
-1.0% |
-1.0% |
867 |
838 |
3.5% |
3.8% |
-0.3% |
|||||||
STELARA |
|||||||||||||||||
US |
680 |
559 |
21.6% |
21.6% |
- |
1,227 |
1,070 |
14.7% |
14.7% |
- |
|||||||
Intl |
303 |
245 |
23.7% |
27.5% |
-3.8% |
579 |
469 |
23.5% |
26.8% |
-3.3% |
|||||||
WW |
983 |
804 |
22.3% |
23.4% |
-1.1% |
1,806 |
1,539 |
17.3% |
18.3% |
-1.0% |
|||||||
OTHER IMMUNOLOGY |
|||||||||||||||||
US |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
|||||||
Intl |
7 |
6 |
16.7% |
15.8% |
0.9% |
14 |
12 |
16.7% |
14.0% |
2.7% |
|||||||
WW |
7 |
6 |
16.7% |
15.8% |
0.9% |
14 |
12 |
16.7% |
14.0% |
2.7% |
|||||||
INFECTIOUS DISEASES |
|||||||||||||||||
US |
341 |
362 |
-5.8% |
-5.8% |
- |
667 |
720 |
-7.4% |
-7.4% |
- |
|||||||
Intl |
451 |
467 |
-3.4% |
-1.5% |
-1.9% |
874 |
885 |
-1.2% |
0.6% |
-1.8% |
|||||||
WW |
792 |
829 |
-4.5% |
-3.4% |
-1.1% |
1,541 |
1,605 |
-4.0% |
-3.0% |
-1.0% |
|||||||
EDURANT |
|||||||||||||||||
US |
17 |
14 |
21.4% |
21.4% |
- |
29 |
25 |
16.0% |
16.0% |
- |
|||||||
Intl |
162 |
126 |
28.6% |
30.9% |
-2.3% |
299 |
234 |
27.8% |
30.6% |
-2.8% |
|||||||
WW |
179 |
140 |
27.9% |
30.0% |
-2.1% |
328 |
259 |
26.6% |
29.2% |
-2.6% |
|||||||
PREZISTA / PREZCOBIX / REZOLSTA |
|||||||||||||||||
US |
278 |
273 |
1.8% |
1.8% |
- |
537 |
550 |
-2.4% |
-2.4% |
- |
|||||||
Intl |
176 |
186 |
-5.4% |
-2.9% |
-2.5% |
347 |
361 |
-3.9% |
-1.4% |
-2.5% |
|||||||
WW |
454 |
459 |
-1.1% |
-0.1% |
-1.0% |
884 |
911 |
-3.0% |
-2.0% |
-1.0% |
|||||||
OTHER INFECTIOUS DISEASES |
|||||||||||||||||
US |
46 |
75 |
-38.7% |
-38.7% |
- |
101 |
145 |
-30.3% |
-30.3% |
- |
|||||||
Intl |
113 |
155 |
-27.1% |
-26.3% |
-0.8% |
228 |
290 |
-21.4% |
-21.5% |
0.1% |
|||||||
WW |
159 |
230 |
-30.9% |
-30.4% |
-0.5% |
329 |
435 |
-24.4% |
-24.4% |
0.0% |
|||||||
See footnotes at end of schedule |
|||||||||||||||||
REPORTED SALES vs. PRIOR PERIOD ($MM) |
|||||||||||||||||
SECOND QUARTER |
SIX MONTHS |
||||||||||||||||
% Change |
% Change |
||||||||||||||||
2017 |
2016 |
Reported |
Operational (1) |
Currency |
2017 |
2016 |
Reported |
Operational (1) |
Currency |
||||||||
NEUROSCIENCE |
|||||||||||||||||
US |
620 |
695 |
-10.8% |
-10.8% |
- |
1,284 |
1,375 |
-6.6% |
-6.6% |
- |
|||||||
Intl |
847 |
907 |
-6.6% |
-4.1% |
-2.5% |
1,680 |
1,776 |
-5.4% |
-3.5% |
-1.9% |
|||||||
WW |
1,467 |
1,602 |
-8.4% |
-7.0% |
-1.4% |
2,964 |
3,151 |
-5.9% |
-4.9% |
-1.0% |
|||||||
CONCERTA / METHYLPHENIDATE |
|||||||||||||||||
US |
76 |
129 |
-41.1% |
-41.1% |
- |
184 |
263 |
-30.0% |
-30.0% |
- |
|||||||
Intl |
105 |
109 |
-3.7% |
-1.3% |
-2.4% |
206 |
206 |
0.0% |
1.3% |
-1.3% |
|||||||
WW |
181 |
238 |
-23.9% |
-22.8% |
-1.1% |
390 |
469 |
-16.8% |
-16.2% |
-0.6% |
|||||||
INVEGA SUSTENNA / XEPLION / TRINZA |
|||||||||||||||||
US |
387 |
339 |
14.2% |
14.2% |
- |
759 |
644 |
17.9% |
17.9% |
- |
|||||||
Intl |
242 |
221 |
9.5% |
13.1% |
-3.6% |
474 |
429 |
10.5% |
13.7% |
-3.2% |
|||||||
WW |
629 |
560 |
12.3% |
13.7% |
-1.4% |
1,233 |
1,073 |
14.9% |
16.2% |
-1.3% |
|||||||
RISPERDAL CONSTA |
|||||||||||||||||
US |
91 |
100 |
-9.0% |
-9.0% |
- |
186 |
195 |
-4.6% |
-4.6% |
- |
|||||||
Intl |
116 |
130 |
-10.8% |
-8.1% |
-2.7% |
228 |
266 |
-14.3% |
-12.0% |
-2.3% |
|||||||
WW |
207 |
230 |
-10.0% |
-8.5% |
-1.5% |
414 |
461 |
-10.2% |
-8.9% |
-1.3% |
|||||||
OTHER NEUROSCIENCE |
|||||||||||||||||
US |
66 |
127 |
-48.0% |
-48.0% |
- |
155 |
273 |
-43.2% |
-43.2% |
- |
|||||||
Intl |
384 |
447 |
-14.1% |
-12.1% |
-2.0% |
772 |
875 |
-11.8% |
-10.6% |
-1.2% |
|||||||
WW |
450 |
574 |
-21.6% |
-20.0% |
-1.6% |
927 |
1,148 |
-19.3% |
-18.4% |
-0.9% |
|||||||
ONCOLOGY |
|||||||||||||||||
US |
697 |
569 |
22.5% |
22.5% |
- |
1,361 |
1,118 |
21.7% |
21.7% |
- |
|||||||
Intl |
1,030 |
905 |
13.8% |
17.0% |
-3.2% |
1,960 |
1,710 |
14.6% |
17.6% |
-3.0% |
|||||||
WW |
1,727 |
1,474 |
17.2% |
19.2% |
-2.0% |
3,321 |
2,828 |
17.4% |
19.2% |
-1.8% |
|||||||
DARZALEX |
|||||||||||||||||
US |
212 |
95 |
* |
* |
- |
413 |
196 |
* |
* |
- |
|||||||
Intl |
87 |
13 |
* |
* |
** |
141 |
13 |
* |
* |
** |
|||||||
WW |
299 |
108 |
* |
* |
** |
554 |
209 |
* |
* |
** |
|||||||
IMBRUVICA |
|||||||||||||||||
US |
202 |
144 |
40.3% |
40.3% |
- |
392 |
276 |
42.0% |
42.0% |
- |
|||||||
Intl |
248 |
151 |
64.2% |
69.4% |
-5.2% |
467 |
280 |
66.8% |
71.4% |
-4.6% |
|||||||
WW |
450 |
295 |
52.5% |
55.1% |
-2.6% |
859 |
556 |
54.5% |
56.8% |
-2.3% |
|||||||
VELCADE |
|||||||||||||||||
US |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
|||||||
Intl |
290 |
342 |
-15.2% |
-12.6% |
-2.6% |
570 |
646 |
-11.8% |
-9.0% |
-2.8% |
|||||||
WW |
290 |
342 |
-15.2% |
-12.6% |
-2.6% |
570 |
646 |
-11.8% |
-9.0% |
-2.8% |
|||||||
ZYTIGA |
|||||||||||||||||
US |
241 |
286 |
-15.7% |
-15.7% |
- |
474 |
558 |
-15.1% |
-15.1% |
- |
|||||||
Intl |
317 |
315 |
0.6% |
3.2% |
-2.6% |
607 |
601 |
1.0% |
3.0% |
-2.0% |
|||||||
WW |
558 |
601 |
-7.2% |
-5.8% |
-1.4% |
1,081 |
1,159 |
-6.7% |
-5.7% |
-1.0% |
|||||||
OTHER ONCOLOGY |
|||||||||||||||||
US |
42 |
44 |
-4.5% |
-4.5% |
- |
82 |
88 |
-6.8% |
-6.8% |
- |
|||||||
Intl |
88 |
84 |
4.8% |
7.1% |
-2.3% |
175 |
170 |
2.9% |
5.5% |
-2.6% |
|||||||
WW |
130 |
128 |
1.6% |
3.1% |
-1.5% |
257 |
258 |
-0.4% |
1.3% |
-1.7% |
|||||||
PULMONARY HYPERTENSION (5) |
|||||||||||||||||
US |
40 |
- |
** |
** |
- |
40 |
- |
** |
** |
- |
|||||||
Intl |
51 |
- |
** |
** |
- |
51 |
- |
** |
** |
- |
|||||||
WW |
91 |
- |
** |
** |
- |
91 |
- |
** |
** |
- |
|||||||
OPSUMIT |
- |
||||||||||||||||
US |
24 |
- |
** |
** |
- |
24 |
- |
** |
** |
- |
|||||||
Intl |
21 |
- |
** |
** |
- |
21 |
- |
** |
** |
- |
|||||||
WW |
45 |
- |
** |
** |
- |
45 |
- |
** |
** |
- |
|||||||
TRACLEER |
- |
||||||||||||||||
US |
2 |
- |
** |
** |
- |
2 |
- |
** |
** |
- |
|||||||
Intl |
24 |
- |
** |
** |
- |
24 |
- |
** |
** |
- |
|||||||
WW |
26 |
- |
** |
** |
- |
26 |
- |
** |
** |
- |
|||||||
UPTRAVI |
- |
||||||||||||||||
US |
8 |
- |
** |
** |
- |
8 |
- |
** |
** |
- |
|||||||
Intl |
1 |
- |
** |
** |
- |
1 |
- |
** |
** |
- |
|||||||
WW |
9 |
- |
** |
** |
- |
9 |
- |
** |
** |
- |
|||||||
OTHER(6) |
- |
||||||||||||||||
US |
6 |
- |
** |
** |
- |
6 |
- |
** |
** |
- |
|||||||
Intl |
5 |
- |
** |
** |
- |
5 |
- |
** |
** |
- |
|||||||
WW |
11 |
- |
** |
** |
- |
11 |
- |
** |
** |
- |
|||||||
CARDIOVASCULAR / METABOLISM / OTHER |
|||||||||||||||||
US |
1,211 |
1,294 |
-6.4% |
-6.4% |
- |
2,306 |
2,473 |
-6.8% |
-6.8% |
- |
|||||||
Intl |
388 |
417 |
-7.0% |
-3.0% |
-4.0% |
768 |
827 |
-7.1% |
-3.7% |
-3.4% |
|||||||
WW |
1,599 |
1,711 |
-6.5% |
-5.5% |
-1.0% |
3,074 |
3,300 |
-6.8% |
-6.0% |
-0.8% |
|||||||
XARELTO |
|||||||||||||||||
US |
642 |
594 |
8.1% |
8.1% |
- |
1,155 |
1,161 |
-0.5% |
-0.5% |
- |
|||||||
Intl |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
|||||||
WW |
642 |
594 |
8.1% |
8.1% |
- |
1,155 |
1,161 |
-0.5% |
-0.5% |
- |
|||||||
INVOKANA / INVOKAMET |
|||||||||||||||||
US |
256 |
348 |
-26.4% |
-26.4% |
- |
503 |
645 |
-22.0% |
-22.0% |
- |
|||||||
Intl |
39 |
35 |
11.4% |
16.8% |
-5.4% |
76 |
63 |
20.6% |
23.9% |
-3.3% |
|||||||
WW |
295 |
383 |
-23.0% |
-22.5% |
-0.5% |
579 |
708 |
-18.2% |
-17.9% |
-0.3% |
|||||||
PROCRIT / EPREX |
|||||||||||||||||
US |
174 |
230 |
-24.3% |
-24.3% |
- |
343 |
413 |
-16.9% |
-16.9% |
- |
|||||||
Intl |
81 |
92 |
-12.0% |
-9.7% |
-2.3% |
159 |
183 |
-13.1% |
-11.3% |
-1.8% |
|||||||
WW |
255 |
322 |
-20.8% |
-20.1% |
-0.7% |
502 |
596 |
-15.8% |
-15.3% |
-0.5% |
|||||||
OTHER |
|||||||||||||||||
US |
139 |
122 |
13.9% |
13.9% |
- |
305 |
254 |
20.1% |
20.1% |
- |
|||||||
Intl |
268 |
290 |
-7.6% |
-3.3% |
-4.3% |
533 |
581 |
-8.3% |
-4.4% |
-3.9% |
|||||||
WW |
407 |
412 |
-1.2% |
1.9% |
-3.1% |
838 |
835 |
0.4% |
3.1% |
-2.7% |
|||||||
TOTAL PHARMACEUTICAL |
|||||||||||||||||
US |
5,010 |
5,144 |
-2.6% |
-2.6% |
- |
9,882 |
10,081 |
-2.0% |
-2.0% |
- |
|||||||
Intl |
3,625 |
3,510 |
3.3% |
6.1% |
-2.8% |
6,998 |
6,751 |
3.7% |
5.9% |
-2.2% |
|||||||
WW |
$ 8,635 |
8,654 |
-0.2% |
1.0% |
-1.2% |
$ 16,880 |
16,832 |
0.3% |
1.2% |
-0.9% |
|||||||
See footnotes at end of schedule |
|||||||||||||||||
REPORTED SALES vs. PRIOR PERIOD ($MM) |
|||||||||||||||||
SECOND QUARTER |
SIX MONTHS |
||||||||||||||||
% Change |
% Change |
||||||||||||||||
MEDICAL DEVICES SEGMENT (2) |
2017 |
2016 |
Reported |
Operational (1) |
Currency |
2017 |
2016 |
Reported |
Operational (1) |
Currency |
|||||||
CARDIOVASCULAR |
|||||||||||||||||
US |
$ 265 |
235 |
12.8% |
12.8% |
- |
$ 524 |
466 |
12.4% |
12.4% |
- |
|||||||
Intl |
258 |
235 |
9.8% |
12.3% |
-2.5% |
498 |
447 |
11.4% |
13.2% |
-1.8% |
|||||||
WW |
523 |
470 |
11.3% |
12.6% |
-1.3% |
1,022 |
913 |
11.9% |
12.8% |
-0.9% |
|||||||
DIABETES CARE |
|||||||||||||||||
US |
160 |
177 |
-9.6% |
-9.6% |
- |
314 |
357 |
-12.0% |
-12.0% |
- |
|||||||
Intl |
261 |
294 |
-11.2% |
-9.5% |
-1.7% |
506 |
543 |
-6.8% |
-5.5% |
-1.3% |
|||||||
WW |
421 |
471 |
-10.6% |
-9.5% |
-1.1% |
820 |
900 |
-8.9% |
-8.1% |
-0.8% |
|||||||
DIAGNOSTICS |
|||||||||||||||||
US |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
|||||||
Intl |
- |
31 |
** |
** |
** |
1 |
59 |
** |
** |
** |
|||||||
WW |
- |
31 |
** |
** |
** |
1 |
59 |
** |
** |
** |
|||||||
ORTHOPAEDICS |
|||||||||||||||||
US |
1,387 |
1,364 |
1.7% |
1.7% |
- |
2,766 |
2,756 |
0.4% |
0.4% |
- |
|||||||
Intl |
956 |
991 |
-3.5% |
-1.4% |
-2.1% |
1,902 |
1,940 |
-2.0% |
-0.3% |
-1.7% |
|||||||
WW |
2,343 |
2,355 |
-0.5% |
0.4% |
-0.9% |
4,668 |
4,696 |
-0.6% |
0.1% |
-0.7% |
|||||||
HIPS |
|||||||||||||||||
US |
208 |
197 |
5.6% |
5.6% |
- |
417 |
400 |
4.3% |
4.3% |
- |
|||||||
Intl |
142 |
152 |
-6.6% |
-4.3% |
-2.3% |
285 |
291 |
-2.1% |
-0.1% |
-2.0% |
|||||||
WW |
350 |
349 |
0.3% |
1.3% |
-1.0% |
702 |
691 |
1.6% |
2.4% |
-0.8% |
|||||||
KNEES |
|||||||||||||||||
US |
236 |
229 |
3.1% |
3.1% |
- |
482 |
473 |
1.9% |
1.9% |
- |
|||||||
Intl |
149 |
156 |
-4.5% |
-2.5% |
-2.0% |
301 |
301 |
0.0% |
2.1% |
-2.1% |
|||||||
WW |
385 |
385 |
0.0% |
0.8% |
-0.8% |
783 |
774 |
1.2% |
2.0% |
-0.8% |
|||||||
TRAUMA |
|||||||||||||||||
US |
390 |
381 |
2.4% |
2.4% |
- |
781 |
762 |
2.5% |
2.5% |
- |
|||||||
Intl |
253 |
255 |
-0.8% |
1.1% |
-1.9% |
504 |
516 |
-2.3% |
-1.0% |
-1.3% |
|||||||
WW |
643 |
636 |
1.1% |
1.9% |
-0.8% |
1,285 |
1,278 |
0.5% |
1.0% |
-0.5% |
|||||||
SPINE & OTHER |
|||||||||||||||||
US |
553 |
557 |
-0.7% |
-0.7% |
- |
1,086 |
1,121 |
-3.1% |
-3.1% |
- |
|||||||
Intl |
412 |
428 |
-3.7% |
-1.6% |
-2.1% |
812 |
832 |
-2.4% |
-0.7% |
-1.7% |
|||||||
WW |
965 |
985 |
-2.0% |
-1.1% |
-0.9% |
1,898 |
1,953 |
-2.8% |
-2.1% |
-0.7% |
|||||||
SURGERY |
|||||||||||||||||
US |
1,012 |
1,020 |
-0.8% |
-0.8% |
- |
2,007 |
2,001 |
0.3% |
0.3% |
- |
|||||||
Intl |
1,372 |
1,377 |
-0.4% |
1.6% |
-2.0% |
2,648 |
2,624 |
0.9% |
2.4% |
-1.5% |
|||||||
WW |
2,384 |
2,397 |
-0.5% |
0.6% |
-1.1% |
4,655 |
4,625 |
0.6% |
1.5% |
-0.9% |
|||||||
ADVANCED |
|||||||||||||||||
US |
400 |
389 |
2.8% |
2.8% |
- |
792 |
741 |
6.9% |
6.9% |
- |
|||||||
Intl |
533 |
520 |
2.5% |
4.9% |
-2.4% |
1,018 |
984 |
3.5% |
5.4% |
-1.9% |
|||||||
WW |
933 |
909 |
2.6% |
4.0% |
-1.4% |
1,810 |
1,725 |
4.9% |
6.0% |
-1.1% |
|||||||
GENERAL |
|||||||||||||||||
US |
423 |
421 |
0.5% |
0.5% |
- |
846 |
840 |
0.7% |
0.7% |
- |
|||||||
Intl |
691 |
706 |
-2.1% |
-0.2% |
-1.9% |
1,342 |
1,357 |
-1.1% |
0.4% |
-1.5% |
|||||||
WW |
1,114 |
1,127 |
-1.2% |
0.0% |
-1.2% |
2,188 |
2,197 |
-0.4% |
0.5% |
-0.9% |
|||||||
SPECIALTY |
|||||||||||||||||
US |
189 |
210 |
-10.0% |
-10.0% |
- |
369 |
420 |
-12.1% |
-12.1% |
- |
|||||||
Intl |
148 |
151 |
-2.0% |
-1.0% |
-1.0% |
288 |
283 |
1.8% |
1.7% |
0.1% |
|||||||
WW |
337 |
361 |
-6.6% |
-6.2% |
-0.4% |
657 |
703 |
-6.5% |
-6.5% |
0.0% |
|||||||
VISION CARE |
|||||||||||||||||
US |
405 |
248 |
63.3% |
63.3% |
- |
710 |
490 |
44.9% |
44.9% |
- |
|||||||
Intl |
650 |
437 |
48.7% |
50.3% |
-1.6% |
1,143 |
835 |
36.9% |
37.6% |
-0.7% |
|||||||
WW |
1,055 |
685 |
54.0% |
55.0% |
-1.0% |
1,853 |
1,325 |
39.8% |
40.2% |
-0.4% |
|||||||
CONTACT LENSES / OTHER |
|||||||||||||||||
US |
274 |
248 |
10.5% |
10.5% |
- |
530 |
490 |
8.2% |
8.2% |
- |
|||||||
Intl |
479 |
437 |
9.6% |
11.2% |
-1.6% |
906 |
835 |
8.5% |
9.2% |
-0.7% |
|||||||
WW |
753 |
685 |
9.9% |
10.9% |
-1.0% |
1,436 |
1,325 |
8.4% |
8.8% |
-0.4% |
|||||||
SURGICAL |
|||||||||||||||||
US |
131 |
- |
** |
** |
- |
180 |
- |
** |
** |
- |
|||||||
Intl |
171 |
- |
** |
** |
- |
237 |
- |
** |
** |
- |
|||||||
WW |
302 |
- |
** |
** |
- |
417 |
- |
** |
** |
- |
|||||||
TOTAL MEDICAL DEVICES |
|||||||||||||||||
US |
3,229 |
3,044 |
6.1% |
6.1% |
- |
6,321 |
6,070 |
4.1% |
4.1% |
- |
|||||||
Intl |
3,497 |
3,365 |
3.9% |
5.8% |
-1.9% |
6,698 |
6,448 |
3.9% |
5.3% |
-1.4% |
|||||||
WW |
$ 6,726 |
6,409 |
4.9% |
5.9% |
-1.0% |
$ 13,019 |
12,518 |
4.0% |
4.7% |
-0.7% |
|||||||
* Percentage greater than 100% |
|||||||||||||||||
** Not meaningful |
|||||||||||||||||
(1) Operational growth excludes the effect of translational currency |
|||||||||||||||||
(2) Unaudited |
|||||||||||||||||
(3) Prior year amounts have been reclassified to conform to current year product disclosure |
|||||||||||||||||
(4) Reported as |
|||||||||||||||||
(5) Actelion acquisition completed |
|||||||||||||||||
(6) Includes Non-Pulmonary Hypertension products |
View original content with multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2017-second-quarter-results-300489759.html
SOURCE
News Provided by Acquire Media